Amgen Inc. (AMGN) vs Johnson & Johnson (JNJ)
Amgen Inc. and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $652.8B against $219.1B — 3.0× the size. Amgen Inc. trades at the lower P/E: 25.6× against 31.4×. Amgen Inc. grew revenue faster over the last twelve months: 9.10% against 8.06%. Amgen Inc. has the higher net margin (23.0% vs 21.5%) and the lower return on invested capital (13.0% vs 15.5%). Both pay a dividend; Amgen Inc. yields more (3.16% vs 3.07%). Across the 23 metrics below, Amgen Inc. leads on 15 and Johnson & Johnson on 8.
Valuation
Profitability
| Metric | AMGN | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.52% | 67.91% | 72.77% |
| Operating margin | 29.99% | 27.69% | 18.90% |
| Net margin | 22.95% | 21.48% | 8.27% |
| Free cash flow margin | 26.71% | 23.20% | 17.25% |
| Return on equity | 91.47% | 25.74% | 6.97% |
| Return on assets | 9.53% | 10.67% | 2.76% |
| Return on invested capital | 12.98% | 15.51% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack